Insider buying last 90 days
No open-market insider purchases were filed for ICL in the last 90 days.
From Form 4 filings, dated to when each was filed.
This week's attention on ICL centers on the approaching third-quarter 2026 results, set for release on 11 November before the Tel Aviv Stock Exchange opens, with CEO Elad Aharonson and CFO Asaf Alperovitz hosting a conference call to discuss results and operating outlook. Commentary ahead of the report notes that ICL does not currently carry the combination of factors typically associated with an earnings beat. Separately, a filing disclosed that an investor reported beneficial ownership of a stake in ICL Group through subsidiaries.
ICL closed at $4.68, unchanged on the day and below both its 50-day average of $5.13 and 200-day average of $5.37, with the 50-day also under the 200-day. Shares sit within the 52-week range of $4.35 to $6.97, down 6.8% over one month, 12.4% over three months, and 15.1% over the past year. The GekkoIndex reads 61.9, placing ICL in the Accumulation zone, though the index has slipped 9.1 over five days. Price stands 15.2% below the Gekko Fair Value estimate of $5.52.
The most immediate catalyst is the earnings release on 11 November, one day away, which falls inside a typical 20-trading-day holding period and carries an average absolute reaction of 2.8% based on prior reports; the last quarter's result missed estimates slightly, with EPS of $0.09 against a $0.10 estimate. No insider, Congress, or unusual options activity appears in the current window. Seasonally, the next 20 trading days have averaged a 1.9% return over five years, with gains in 3 of those years. Analyst coverage from two firms is currently rated hold, with a consensus target of $5.74.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
ICL scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
Below 50 and 200-day
Close $4.52 is below the 50-day ($5.03) and 200-day ($5.35) averages, and the 50-day is below the 200-day.
See the chart64.6, Accumulation
Reading 64.6 is in the Accumulation zone.
See the GekkoIndex16.3% below
Price is 16.3% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 94 days
Next report Feb 17, 2027, 94 days away — outside a typical 20-trading-day hold.
See earnings+2.3% on average
From this point in the calendar, the next 20 trading days averaged +2.3% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
ICL closed at $4.52 on Nov 13, 2026, −17.8% over the past year, inside a 52-week range of $4.35 to $6.97.
Use the left and right arrow keys to read daily values.
Put ICL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
ICL is a global producer of minerals and chemicals, working across four business units. It extracts bromine from a byproduct of potash production and turns it into bromine-based compounds, alongside potash, salt, magnesium chloride and magnesia products, plus phosphorus-based flame retardants. It also draws potash from the Dead Sea and mines and produces potash and salt more broadly, making it known for its mineral extraction and processing activities.
Beyond raw extraction, ICL converts phosphate commodities into fertilizers, sulphuric acid, and phosphoric acid used across oral hygiene, cleaning, paints and coatings, water treatment, asphalt, construction and metal treatment. It also makes functional food ingredients and phosphate additives for processed meat, poultry, seafood, dairy, beverages and baked goods, as well as milk and whey proteins for the food ingredients industry. Its Innovative Ag Solutions unit develops nitrogen, potash and phosphate fertilizers, including water-soluble, liquid, soluble and controlled-release forms, sold worldwide through marketing firms, agents and distributors.
The company began as Israel Chemicals Ltd, founded in 1968, and took its present name in May 2020. It is headquartered in Tel Aviv, Israel, and its shares trade on the NYSE under the ticker ICL.
ICL’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64.6, in the Accumulation zone, up 2.5 points over five sessions.
Up 2.5 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 55 | +0.9% | +3.0% | ||
| Accumulation (current zone) | 214 | +0.2% | +1.2% | ||
| Neutral | 389 | −0.1% | −0.1% | ||
| Distribution | 37 | +1.3% | −0.3% | ||
| Selling | 7 | Too few readings yet | |||
Average ICL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
ICL trades 16.3% below Gekko Fair Value of $5.40, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what ICL shares are worth, recalculated every trading day.
$5.40
Gekko Fair Value, Nov 14, 2026
16.3% Undervalued
At the end of Aug 2026 the price was 2.0% above the estimate.
No open-market insider purchases were filed for ICL, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for ICL in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in ICL were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
0of the funds Gekko tracks hold ICL.
ICL reports on Feb 17, 2027, before the open (94 days away), and beat the EPS estimate in 4 of its last 8 reports.
Feb 17, 2027
Expected before the open, 94 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Feb 12, 2026 | $0.09 est $0.10 | $1.70B est $1.77B | −0.3% |
| Nov 10, 2025 | $0.10 est $0.11 | $1.85B est $1.95B | +0.4% |
| Aug 6, 2025 | $0.09 est $0.08 | $1.83B est $1.83B | +2.8% |
| May 19, 2025 | $0.09 est $0.08 | $1.77B est $1.82B | −2.5% |
| Feb 26, 2025 | $0.08 est $0.09 | $1.60B est $1.71B | −4.7% |
| Nov 11, 2024 | $0.11 est $0.08 | $1.75B est $1.65B | +3.4% |
| Aug 14, 2024 | $0.10 est $0.09 | $1.75B est $1.76B | +7.3% |
| May 9, 2024 | $0.09 est $0.09 | $1.72B est $1.75B | −1.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for ICL is $5.74, +27.0% from the last close, from 3 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 3 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 12 | BMO Capital | $6 | +32.7% |
| Nov 11 | Barclays | $6 | +32.7% |
| Oct 16 | Morgan Stanley | $5.45 | +20.6% |
| Oct 16 | Barclays | $6 | +32.7% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, ICL averaged +2.3% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.2% | 3 of 5 |
| Next 10 trading days | +1.2% | 3 of 5 |
| Next 15 trading days | +2.0% | 2 of 5 |
| Next 20 trading days | +2.3% | 2 of 5 |
| Next 30 trading days | +1.4% | 3 of 5 |
For scale, ICL’s typical 20-trading-day move in either direction is about 7.1%.
ICL’s market cap is $5.83B, with a P/E ratio of 18 and revenue of $7.77B over the last twelve months.
Coverage of ICL this week reads neutral: 4 positive, 5 neutral and 1 negative headlines.
ICL’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| NTRNutrien | Neutral | 4.2% above |
| CFCF Industries | Neutral | 31.4% below |
| MOSMosaic | Neutral | 14.7% below |
| SMGScotts Miracle-Gro | Neutral | 0.6% below |
| UANCVR Partners | Accumulation | 42.7% below |
| ODCOil-Dri Corporation Of America | Accumulation | 21.4% below |
A peer links to its own page where one exists.
ICL’s market cap is $5.83B at the Nov 13, 2026 close of $4.52, with 1.29B shares outstanding. The shares trade on a P/E ratio of 18.
The consensus analyst 12-month price target for ICL is $5.74, +27.0% from the last close. Of the 3 firms that rated the stock in the last 90 days, 0 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate ICL is undervalued: the Nov 13, 2026 close of $4.52 is 16.3% below Gekko Fair Value of $5.40. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
ICL is expected to report on Feb 17, 2027, before the market opens (94 days away). Analysts expect earnings of $0.09 per share on revenue of $1.92B. ICL beat the earnings estimate in 4 of its last 8 reports, moving 2.8% on average across the report.
ICL’s 52-week high is $6.97 and its 52-week low is $4.35; it closed at $4.52 on Nov 13, 2026, −17.8% over the past year. Over the last five years the shares peaked at $12.96 on Apr 14, 2022.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (seasonality) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.